Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRE Combined With Lenvatinib and Sintilimab for Advanced HCC
NCT07832006Phase 2Recruiting
- Sponsor
- SCG Cell Therapy
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by SCG Cell Therapy. Primary endpoints: Objective Response Rate up to 24 months and Conversion Surgery Rate up to 24 months. Started Apr 2025; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07832006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832006.